
A recent retrospective observational study examined the treatment options for patients with moderate-to-severe or persistent inflammatory arthritis caused by immune checkpoint inhibitor (ICI) therapy for cancer. The study found that while biologic disease-modifying antirheumatic drugs (DMARDs) may lead to faster control of arthritis compared to methotrexate, they are also linked to a shorter time to cancer progression. Therefore, the optimal choice of DMARD for these patients remains uncertain.
Like
Save
Share